Omidenepag isopropyl

Drug Profile

Omidenepag isopropyl

Alternative Names: DE-117

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Ube Industries
  • Developer Santen Pharmaceutical; Ube Industries
  • Class Eye disorder therapies; Prostaglandins; Pyrazoles; Pyridines; Small molecules; Sulfonamides
  • Mechanism of Action Prostaglandin E EP2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glaucoma; Ocular hypertension

Most Recent Events

  • 25 Jan 2017 Santen plans a phase III trial for Glaucoma and Ocular hypertension in Korea and other Asian countries (Santen pipeline, January 2017)
  • 23 Jan 2017 Chemical structure information added
  • 01 Nov 2016 Phase-III clinical trials in Glaucoma in Singapore (Topical) (NCT02981446)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top